Compounded semaglutide price tracker — 6 month update

SarahChen_PharmD said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

steph_laguna said:

The mechanism that matters here is not stomach emptying, it is central.

That reframing is the part I needed. Adding it to my notes with a link back to this thread.

SarahChen_PharmD said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

The figures, for anyone assembling their own picture. Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Report rather than reply if it drifts again.